Lack of FDA Guidance on KRAS Testing Creates Confusion; Pharmas See Lower Sales | GenomeWeb

The lack of clear guidance from the US Food and Drug Administration regarding KRAS testing to target treatment with anti-EGFR monoclonal antibodies for colorectal cancer is affecting sales of such drugs and putting drugmakers in a difficult spot with regard to what they can and cannot say to doctors.

During an earnings call Last week, BMS said confusion over KRAS testing caused fourth-quarter US sales of its colorectal cancer drug Erbitux to slide 2 percent to $179 million from the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.